Intended for healthcare professionals

CCBYNC Open access
Research

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials

BMJ 2019; 365 doi: https://doi.org/10.1136/bmj.l1328 (Published 09 April 2019) Cite this as: BMJ 2019;365:l1328